| [伍素瑩] 期刊論文 |
2019-04-10 |
Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants |
- |
 |
| [其他] 期刊論文 |
2013-08 |
Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma |
- |
|
| [其他] 期刊論文 |
2021-07-26 |
Cancer registry coding via hybrid neural symbolic systems in the cross-hospital setting |
- |
|
| [其他] 期刊論文 |
2018-04 |
Dialysis increases the risk of bladder recurrence in patients with Upper Tract Urothelial Cancer: A population-based study |
- |
|
| [劉敏(1996-2007)] 期刊論文 |
1997-07 |
Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers - An effective and low-toxic regimen for patients with poor general condition |
- |
|
| [劉敏(1996-2007)] 期刊論文 |
1997-04 |
Mitomycin-C induced hemolytic uremic syndrome: A case report and literature review |
- |
|
| [劉滄梧] 會議論文/會議摘要 |
1999-09 |
A multi-centre phase II trial of gemcitabine (GEM) and vinorelbine (VRL) in patients (PTS) with stage III-IV non small cell lung cancer (NSCLC) |
- |
|
| [劉滄梧] 期刊論文 |
2020-07-01 |
A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue |
- |
|
| [劉滄梧] 期刊論文 |
2010-01-27 |
Is quality of colorectal cancer care good enough? Core measures development and its application for comparing hospitals in Taiwan |
- |
|
| [劉滄梧] 期刊論文 |
2006-11 |
Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma |
- |
|
| [劉滄梧] 期刊論文 |
2004-09 |
Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: A preliminary study |
- |
|
| [夏和雄(1996-2012)] 會議論文/會議摘要 |
2011-04 |
Activation of Akt/FoxO axis confers resistance to cisplatin in human nasopharyngeal carcinomas |
- |
|
| [夏興國] 期刊論文 |
2022-05 |
Transcriptional suppression of Dicer by HOXB-AS3/EZH2 complex dictates sorafenib resistance and cancer stemness |
- |
|
| [姜乃榕] 會議論文/會議摘要 |
2023-06 |
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors |
- |
|
| [姜乃榕] 會議論文/會議摘要 |
2022-06 |
Comparative genomic analysis and its prognostic impact on survival between viral hepatitis-related and non-viral hepatitis intrahepatic cholangiocarcinoma |
- |
|
| [姜乃榕] 會議論文/會議摘要 |
2022-02 |
Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors |
- |
|
| [姜乃榕] 會議論文/會議摘要 |
2021-05 |
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma |
- |
|
| [姜乃榕] 會議論文/會議摘要 |
2021-05 |
A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy |
- |
|
| [姜乃榕] 會議論文/會議摘要 |
2019-02 |
Mutational landscape by targeted next-generation sequencing in EBV-associated lymphoepithelioma-like cholangiocarcinoma |
- |
|
| [姜乃榕] 會議論文/會議摘要 |
2018-10 |
Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study |
- |
|
| [姜乃榕] 會議論文/會議摘要 |
2017-02 |
A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer |
- |
|
| [姜乃榕] 會議論文/會議摘要 |
2016-02 |
Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy |
- |
|
| [姜乃榕] 會議論文/會議摘要 |
2016-02 |
Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC) |
- |
|
| [姜乃榕] 期刊論文 |
2022-10 |
The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma |
- |
|
| [姜乃榕] 期刊論文 |
2022-09-15 |
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin |
- |
|
| [姜乃榕] 期刊論文 |
2022-09 |
A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study |
- |
|
| [姜乃榕] 期刊論文 |
2022-06 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin |
- |
|
| [姜乃榕] 期刊論文 |
2022-04-15 |
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan |
- |
|
| [姜乃榕] 期刊論文 |
2017-05 |
A phase I dose escalation study of SCBO1A, a micro tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy |
- |
|
| [常慧如] 會議論文/會議摘要 |
2018-10 |
Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study |
- |
|
| [常慧如] 期刊論文 |
2018-04 |
The role of consolidation chemoradiotherapy in Locally Advanced Pancreatic Cancer receiving chemotherapy: An updated systematic review and meta-analysis |
- |
|
| [常慧如] 期刊論文 |
2015-04 |
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide |
- |
|
| [廖倫德] 期刊論文 |
2024-06-21 |
Topiramate suppresses peri-infarct spreading depolarization and improves outcomes in a rat model of photothrombotic stroke |
- |
|
| [廖倫德] 期刊論文 |
2023-01-06 |
Visible CCD camera-guided photoacoustic imaging system for precise navigation during functional rat brain imaging |
- |
|
| [廖倫德] 期刊論文 |
2022-11-01 |
Revisiting the cerebral hemodynamics of awake, freely moving rats with repeated ketamine self-administration using a miniature photoacoustic imaging system |
- |
|
| [廖倫德] 期刊論文 |
2021-10-30 |
Assessment of brain functional activity using a miniaturized head-mounted scanning photoacoustic imaging system in awake and freely moving rats |
- |
|
| [廖倫德] 期刊論文 |
2021-08-03 |
An adjustable dark-field acoustic-resolution photoacoustic imaging system with fiber bundle-based illumination |
- |
|
| [廖倫德] 期刊論文 |
2021-06-07 |
In vivo assessment of hypoxia levels in pancreatic tumors using a dual-modality ultrasound/photoacoustic imaging system |
- |
|
| [廖倫德] 期刊論文 |
2019-11-27 |
Characterization of a fiber bundle-based real-time ultrasound/photoacoustic imaging system and its in vivo functional imaging applications |
- |
|
| [廖倫德] 期刊論文 |
2019-07 |
Preventive hypothermia as a neuroprotective strategy for paclitaxel-induced peripheral neuropathy |
- |
|
| [張俊彥] 會議論文/會議摘要 |
2004-08-02 |
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer |
- |
|
| [張俊彥] 期刊論文 |
2013-03-12 |
A novel synthetic microtubule inhibitor, MPT0B214 exhibits antitumor activity in human tumor cells through mitochondria-dependent intrinsic pathway |
- |
|
| [張俊彥] 期刊論文 |
2012-06-15 |
Targeted Casp8AP2 methylation increases drug resistance in mesenchymal stem cells and cancer cells |
- |
|
| [張俊彥] 期刊論文 |
2011-12-15 |
Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors |
- |
|
| [張俊彥] 期刊論文 |
2011-10-01 |
Enhancement of non-homologous end joining DNA repair capacity confers cancer cells resistance to the novel selenophene compound, D-501036 |
- |
|
| [張俊彥] 期刊論文 |
2010-05 |
Chamaecypanone C, a novel skeleton microtubule inhibitor, with anticancer activity by trigger caspase 8-Fas/FasL dependent apoptotic pathway in human cancer cells |
- |
|
| [張俊彥] 期刊論文 |
2009-04-17 |
Synthesis and structure-activity relationships of 1-benzyl-4,5,6-trimethoxyindoles as a novel class of potent antimitotic agents |
- |
|
| [張俊彥] 期刊論文 |
2008-08 |
Transcriptional repression of O-6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N '-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells |
- |
|
| [張俊彥] 期刊論文 |
2007-07-31 |
Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil |
- |
|
| [張俊彥] 期刊論文 |
2004-07-15 |
A novel bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid carcinoma cells |
- |
|
| [張俊彥] 期刊論文 |
2004-07-01 |
BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo |
- |
|
| [張俊彥] 期刊論文 |
2002 |
A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer |
- |
|
| [張光裕] 會議論文/會議摘要 |
2018-05 |
A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers |
- |
|
| [張光裕] 會議論文/會議摘要 |
2014-05 |
A phase I dose escalation study of weekly BI 836845, a fully human, affinity-optineized, insulin -like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid cancers |
- |
|
| [張文祥] 期刊論文 |
2022-04-11 |
Identification of distinct slow mode of reversible adaptation of pancreatic ductal adenocarcinoma to the prolonged acidic pH microenvironment |
- |
|
| [張書銘] 會議論文/會議摘要 |
2018-12 |
The epidemiology of gastric cancer in the era of H. pylori eradication: A nation-wide registry-based study in Taiwan |
- |
|
| [張書銘] 會議論文/會議摘要 |
2018-01 |
Environmental tobacco smoke and risk of pancreatic cancer among never smokers |
- |
|
| [張書銘] 會議論文/會議摘要 |
2015-08 |
The association between periodontal disease and pancreatic cancer |
- |
|
| [張書銘] 期刊論文 |
2021-07-15 |
No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol |
- |
|
| [張書銘] 期刊論文 |
2020-05-26 |
Validation of genome-wide association study-identified single nucleotide polymorphisms in a case-control study of pancreatic cancer from Taiwan |
- |
|
| [張書銘] 期刊論文 |
2015-06 |
Comprehensive analysis of the incidence and survival patterns of lung cancer by histologies, including rare subtypes, in the era of molecular medicine and targeted therapy: A nation-wide cancer registry-based study from Taiwan |
- |
|
| [張書銘] 期刊論文 |
2014-02 |
The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998-2008: A nation-wide cancer registry-based study |
- |
|
| [張書銘] 期刊論文 |
2013-12-31 |
Second cancers in patients with neuroendocrine tumors |
- |
|
| [張書銘] 期刊論文 |
2013-04-22 |
The epidemiology of neuroendocrine tumors in Taiwan: A nation-wide cancer registry-based study |
- |
|
| [張書銘] 期刊論文 |
2012-02 |
Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2010-09 |
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2009-12 |
Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2005-12 |
Pulmonary embolism after transcatheter arterial chemoembolization |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2005-09-21 |
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2005-09-14 |
Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2005-09 |
Long-term complete remission of metastatic gastric cancer after weekly docetaxel, 24 h infusion of high-dose 5-FU/leucovorin and cisplatin |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2005-08-01 |
alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2004-12 |
Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2004-04-15 |
Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2003-06 |
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2002-07 |
Palliative meflep therapy in advanced pancreatic cancer: Excellent response in a patient with her-2/neu amplification |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2002-05 |
Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
2000-02 |
In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
1999-08 |
The status of the do-not-resuscitate order in Chinese clinical trial patients in a cancer centre |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
1999-07 |
A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells |
- |
|
| [彭汪嘉康(1996-2007)] 期刊論文 |
1996-07-17 |
Paclitaxel-induced severe neuropathy in patients with previous radiotherapy to the head and neck region |
- |
|
| [施能耀] 專利 |
2023-09-01 |
可標靶ＶＥＧＦＲ２與ＶＥＧＦＲ３的雙功能抗體 |
- |
|
| [施能耀] 專利 |
2023-04-11 |
Dual-function antibodies targeting VEGFR2 and VEGFR3 |
- |
|
| [施能耀] 專利 |
2023-03-30 |
Dual-function antibodies targeting VEGFR2 and VEGFR3 |
- |
|
| [施能耀] 會議論文/會議摘要 |
2012-03 |
Involvement of autophagy in endogenous and NVP-AUY922-induced C-kit degradation in both imatinib-sensitive and -resistant gastrointestinal stromal tumor cells |
- |
|
| [施能耀] 期刊論文 |
2016-05 |
Overexpression of regulator of G protein signaling 11 promotes cell migration and associates with advanced stages and aggressiveness of lung adenocarcinoma |
- |
|
| [楊奕馨] 期刊論文 |
2021-11-30 |
Survival outcomes of management in metastatic gastric adenocarcinoma patients |
- |
|
| [沈哲宏] 期刊論文 |
2023-01 |
TRPM1 promotes tumor progression in acral melanoma by activating the Ca2+/CaMKIIdelta/AKT pathway |
- |
|
| [洪文俊] 會議論文/會議摘要 |
2018-12 |
c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation |
- |
|
| [洪文俊] 會議論文/會議摘要 |
2016-11 |
Role of epigenetic regulator EHMT2 in the regulation of gemcitabine resistance in pancreatic cancer |
- |
|
| [洪文俊] 期刊論文 |
2024-03 |
RNF43 inactivation enhances the B-RAF/MEK signaling and greates a combinatory therapeutic target in cancer cells |
- |
|
| [洪文俊] 期刊論文 |
2023-01-20 |
ARID1A loss in pancreas leads to islet developmental defect and metabolic disturbance |
- |
|
| [洪文俊] 期刊論文 |
2022-04-18 |
The trinity: Interplay among cancer cells, fibroblasts, and immune cells in pancreatic cancer and implication of CD8(+) T cell-orientated therapy |
- |
|
| [洪文俊] 期刊論文 |
2019-07 |
Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer |
- |
|
| [洪文俊] 期刊論文 |
2019-06-24 |
Alteration of epigenetic modifiers in pancreatic cancer and its clinical implication |
- |
|
| [洪文俊] 期刊論文 |
2019-05-27 |
Deciphering the potential role of hox genes in pancreatic cancer |
- |
|
| [洪文俊] 期刊論文 |
2019-01 |
Beta-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer |
- |
|
| [洪文俊] 期刊論文 |
2018-12-20 |
Protein arginine methyltransferase 3 enhances chemoresistance in pancreatic cancer by methylating hnRNPA1 to increase ABCG2 expression |
- |
|
| [洪文俊] 期刊論文 |
2018-01 |
Orchestration of H3K27 methylation: Mechanisms and therapeutic implication |
- |
|
| [洪文俊] 期刊論文 |
2016-09 |
The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer |
- |
|
| [洪文俊] 期刊論文 |
2015-12-21 |
G9a orchestrates PCL3 and KDM7A to promote histone H3K27 methylation |
- |
|
| [洪文俊] 期刊論文 |
2014-02 |
RECK inhibits stemness gene expression and tumorigenicity of gastric cancer cells by suppressing ADAM-mediated notch1 activation |
- |
|
| [莊雙恩] 期刊論文 |
2016-02 |
Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells |
- |
|
| [蔡坤志] 期刊論文 |
2021-06-22 |
A Novel Invadopodia-Specific Marker for Invasive and Pro-Metastatic Cancer Stem Cells [Erratum:Frontiers in Oncology. 2021 May 31;11:Article number 638311.] |
- |
|
| [蔡坤志] 期刊論文 |
2021-05-31 |
A novel invadopodia-specific marker for invasive and pro-metastatic cancer stem cells |
- |
|
| [蔡坤志] 期刊論文 |
2019-02 |
ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling |
- |
|
| [蔡坤志] 期刊論文 |
2019-02 |
ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling [Erratum: Oncogene. 2019 Feb;38(8):1340-1353.] |
- |
|
| [蔡坤志] 期刊論文 |
2013-11 |
A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression |
- |
|
| [蔡慧珍] 會議論文/會議摘要 |
2023-10 |
Risk of type 2 diabetes mellitus and hyperlipidemia in patients with chronic myeloid leukemia initiating tyrosine kinase inhibitors: A nationwide cohort study |
- |
|
| [蔡慧珍] 會議論文/會議摘要 |
2018-01 |
The role of aberrant mitochondrial phosphoenolpyruvate carboxykinase expression in pancreatic neuroendocrine tumors |
- |
|
| [蔡慧珍] 會議論文/會議摘要 |
2016-02 |
Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors |
- |
|
| [蔡慧珍] 期刊論文 |
2024-11-18 |
Cooperative participation of CagA and NFATc1 in the pathogenesis of antibiotics-responsive gastric MALT lymphoma |
- |
|
| [蔡慧珍] 期刊論文 |
2024-07-11 |
Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: A nationwide registry study |
- |
|
| [蔡慧珍] 期刊論文 |
2022-11-06 |
PTEN regulates invasiveness in pancreatic neuroendocrine tumors through DUSP19-mediated VEGFR3 dephosphorylation |
- |
|
| [蔡慧珍] 期刊論文 |
2021-04-12 |
An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan |
- |
|
| [蔡慧珍] 期刊論文 |
2021-01 |
c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation |
- |
|
| [蔡慧珍] 期刊論文 |
2018-11 |
The incidence and survival of pancreatic cancer by histology, including rare subtypes: A nation-wide cancer registry-based study from Taiwan |
- |
|
| [蔡慧珍] 期刊論文 |
2016-10 |
BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT driven myeloid leukemia |
- |
|
| [蔡慧珍] 期刊論文 |
2016-05 |
Efficacy of frontline antibiotics therapy in the treatment of Helicobacter pylori-negative gastric low-grade mucosa-associated lymphoid tissue lymphoma |
- |
|
| [蔡慧珍] 期刊論文 |
2015-06 |
Helicobacter pylori CagA translocation is closely associated with the expression of CagA-signaling molecules in low-grade gastric mucosa-associated lymphoid tissue lymphoma |
- |
|
| [蔡慧珍] 期刊論文 |
2014-02 |
Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line-A reply: Despite the same 8-code STR, MA-1 and Pfeiffer are cytogenetically diverse |
- |
|
| [蔡慧珍] 期刊論文 |
2013-07 |
Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: Clinical and biological significance |
- |
|
| [蔣維棠] 期刊論文 |
2019-12 |
Identification of a multitargeted tyrosine kinase inhibitor for the treatment of gastrointestinal stromal tumors and acute myeloid leukemia |
- |
|
| [蕭金福] 會議論文/會議摘要 |
2015-12 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial |
- |
|
| [蕭金福] 會議論文/會議摘要 |
2015-05 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial |
- |
|
| [蕭金福] 會議論文/會議摘要 |
2010-11 |
Medical resources utilization of five most prevalent cancers in Taiwan (lung cancer, liver cancer, colorectal cancer, gastric cancer, and brest cancer): 2001 similar to 2007 |
- |
|
| [蕭金福] 期刊論文 |
2021-05 |
High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial |
- |
|
| [蕭金福] 期刊論文 |
2018-07 |
The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients |
- |
|
| [蕭金福] 期刊論文 |
2016-01 |
A phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma: The TCOG 3211 clinical trial |
- |
|
| [蘇勇曄] 會議論文/會議摘要 |
2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome |
- |
|
| [蘇勇曄] 會議論文/會議摘要 |
2023-11 |
Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis |
- |
|
| [蘇勇曄] 會議論文/會議摘要 |
2022-07 |
Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors |
- |
|
| [蘇勇曄] 期刊論文 |
2024-02-01 |
Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma- with emphasis on locoregional therapy for oligoprogression |
- |
|
| [蘇勇曄] 期刊論文 |
2022-09-21 |
Clustering of chromatin remodeling enzymes predicts prognosis and clinical benefit of therapeutic strategy in pancreatic cancer |
- |
|
| [蘇勇曄] 期刊論文 |
2021-11-20 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study |
- |
|
| [蘇振良] 期刊論文 |
2020-01 |
Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer [Erraturm: Oncogene. 2016 May;35(12):1517-1528.] |
- |
|
| [蘇振良] 期刊論文 |
2016-03 |
miR-520h is crucial for DAPK2 regulation and breast cancer progression |
- |
|
| [蘇振良] 期刊論文 |
2016-03 |
Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer |
- |
|
| [邱燕楓] 期刊論文 |
2023-09 |
Carbohydrate antigen 19-9 response to initial adjuvant chemotherapy predicts survival and failure pattern of resected pancreatic adenocarcinoma but not which patients are suited for additional adjuvant chemoradiation therapy: From a prospective randomized study |
- |
|
| [郭靜娟] 期刊論文 |
2013-10 |
Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: The role of IL-6 signaling and Nrf2/AKR1C axis identification |
- |
|
| [鄒小蕙] 會議論文/會議摘要 |
2023-06 |
Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: Focusing on hepatic safety and viral kinetics |
- |
|
| [鄒小蕙] 會議論文/會議摘要 |
2018-11 |
TCOG T1308 study: The final results of a phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer |
- |
|
| [陳立宗] 圖書 |
2017-05-04 |
Chemotherapy in the management of pancreatic cancer |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2022-11 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2022-10 |
Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2022-09 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2022-07 |
Toward collaboration among cancer trials groups in Asia: TCOG perspective |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2022-07 |
Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2022-07 |
A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2022-06 |
Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2022-02-01 |
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2022-02-01 |
A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2021-09 |
INTEGRATE IIb: A randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2021-09 |
Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2021-07 |
Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2021-05 |
Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2020-09 |
Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2020-09 |
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2020-05 |
EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2020-02 |
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2020-02 |
A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2019-10 |
Chemo-radiotherapy in adjuvant therapy of curatively resected pancreatic cancer: Lesions from TCOG T3207 study |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2019-10 |
Interpretation the results of adjuvant chemotherapy in curatively resected pancreatic cancer |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2019-10 |
Randomised phase 3 study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) - Integrate II |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2019-10 |
A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2019-02 |
A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naive, advanced, or metastatic biliary tract cancer (BTC) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2019-02 |
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2 |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2019-02 |
A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-12 |
FOXO3a-driven alternation of metabolism dictates the gemcitabine sensitivity |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-11 |
Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-11 |
M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor beta (TGF-beta) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-10 |
NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-10 |
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-10 |
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1 |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-10 |
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-09 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-05 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-05 |
A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-02 |
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-02 |
Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) +/- 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1. |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-02 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-02 |
Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-02 |
Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) p |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-02 |
Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2018-01 |
Role of academic institute in cancer therapy development in National Institute of Cancer Research, NHRI in Taiwan |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-11 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-11 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) � 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-09 |
ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-09 |
ATTRACTION-05 (ONO-4538-38/BMS CA209844): A randomized, multicenter, double-blind, placebo-controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-09 |
Inhibition of the ubiquitin-conjugating enzyme E2B restores the BCNU sensitivity of cancer cells by regulating MGMT ubiquitination |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-09 |
Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alon |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-09 |
Mutant KIT translocates into the nucleus and induces NFKBIB expression that leads to KIT expression in imatinib-resistant gastrointestinal stromal tumors |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-09 |
Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-09 |
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-06-26 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-06-26 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) +/- 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-05 |
The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-02 |
Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPO |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-02 |
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2017-02 |
Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-12 |
Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-12 |
Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1 |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-12 |
Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors-retrospective multi-center study in Taiwan |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-10 |
Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-b |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-10 |
Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with ge |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-10 |
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-10 |
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-10 |
CagA and NFAT co-operatively participate in the lymphomagenesis of gastric MALT lymphoma |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-06 |
Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-06 |
Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-06 |
Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-05 |
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-05 |
Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-05 |
Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-05 |
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-02 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-02 |
A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2016-02 |
Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2015-09 |
The safety and efficacy of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2015-09 |
Expression of the Helicobater pylori CagA protein is closely associated with Helicobater pylori-dependence of early-stage high-grade gastric lymphoma |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2015-05 |
Heterogeneous cell origin of helicobater pylori-dependent high-grade gastric lymphomas |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2015-05 |
Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative Oncology Group T1206 study |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2015-01 |
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2014-12 |
Pegylated arginine deiminase (ADI-PEG20) in relapsed/refractory and/or elder Acute Myeloid Leukemia: The preliminary result of phase II trial |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2014-10 |
Nuclear expression of BCL10 has a role in the regulation of cell growth and progression of pancreatic cancer through the activation of NF-kappa B-related signaling |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2014-05 |
Using chinese herbal medicine containing mu-tong is associated with upper urinary tract cancer in patient with end-stage renal disease |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2014-05 |
Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2014-05 |
Association of helicobacter pylori CagA translocation with the expression of CagA-signaling transduction molecules in gastric mucosa-associated lymphoid tissue lymphoma |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2014-01 |
EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2014-01 |
Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2013-05 |
Effective treatment of aggressive B-cell lymphomas by downregulated NIK-induced noncanonical NF-kappa B pathway activation through inhibition of BAFF |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2013-05 |
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2013-05 |
Impact of virologic factors on recurrence-free survival in HBV-related hepatocellular carcinoma after surgical resection: Post hoc analysis from a prospective study with long-term follow-up |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2013-03 |
Auy922, a novel Hsp90 inhibitor effective against ABC-dlbcl and malt lymphoma cells harboring genetic alteration-associated NF-kappa B activation |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2012-10 |
Front-line antibiotic therapy in early-stage H. Pylori-positive gastric Diffuse Large B-Cell Lymphomas with or without malt features |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2012-05-20 |
Randomized phase II trial of TACE plus everolimus as first-line therapy in localized unresectable hepatocellular carcinoma (HCC): The TRACER trial |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2012-02 |
Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on firstline oxaliplatin-based chemotherapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2011-11 |
Role of chromogranin a and neuron-specific enolase biomarkers in progression-free survival (PFS) with everolimus (EVE) versus placebo (PB) in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III radiant-3 results |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2011-09 |
Phase II study of low-dose everolimus plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for first-line treatment of metastatic or recurrent gastric cancers |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2011-05 |
Novel Hsp90 inhibitor NVP-AUY922 downregulates mutant c-Kit protein through transcription and enhancing protein degradation via both proteasome and autophagy-mediated pathways |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2011-02 |
Loss of ASS1 expression in myxofibrosarcoma via promoter hypermethylation: Prognostic and potential therapeutic implications |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2011-02 |
Loss of ASS1 expression in myxofibrosarcoma via promoter hypermethylation: Prognostic and potential therapeutic implications |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2009-12 |
A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2009-10 |
Pharmacoeconomic analysis of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) in the first line treatment of metastasis colorectal cancer in Taiwan |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2009-05 |
RAD001 (everolimus) suppresses growth of a gastric MALT lymphoma cell Line via downregulation of pAKT/mTOR and BAFF/NF-\#954;B signal transduction pathways |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2008-05 |
Cost-minimization analysis of capecitabine for advanced gastric cancer in Taiwan |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2008 |
Expression of the nuclear factor kappa B (NFKB) P50/P65 proteins in hepatocellular carcinoma (HCC): Lack of predictive value for response to thalidomide treatment |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2007-09 |
A phase II trial of oxaliplatin with high-dose of 5-fluorouracil and leucovorin in the first-line treatment of inoperable, locally advanced or metastatic biliary tract cancer |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2007-06 |
H pylori-positive gastric diffuse large B-cell lymphomas are potentially curable by H pylori eradication therapy |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2007-05 |
Pharmacoeconomic analysis of capecitabine in adjuvant treatment of stage III colon cancer in Taiwan |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2006-11 |
Combined modalities of resistance in an oxaliplaitin-resistant human gastric cancer cell line with enhanced sensitivity |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2005-06 |
An open, multi-center, phase II clinical trial to evaluate efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer preliminary report |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2004-08 |
Effect of interleukin-1beta and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2004-07 |
Comparison of the antitumor activity of thalidomide between hepatitis B (HBV)and hepatitis C (HCV)-related hepatocellular carcinoma (HCC) |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2004-06 |
Acute hemorrhagic rectal ulcer syndrome: A new clinical entity? Report of 19 cases and review of the literature |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2003-11 |
Use of power Doppler sonography and circulating angiogenic factors to assess the potential antiangiogenic effect of thalidomide in hepatocellular carcinoma |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2002-11 |
Expression of nuclear BCL10 is highly correlated with the expression of nuclear NF-kB and is predictive of Helicobacter pylori-dependent status in early-stage high-grade gastric MALT lymphoma |
- |
|
| [陳立宗] 會議論文/會議摘要 |
2002 |
Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma |
- |
|
| [陳立宗] 會議論文/會議摘要 |
1999-09 |
Prospective study of anti-H. pylori therapy in stage IE high-grade mucosa-associated lymphoid tissue (hg-MALT) lymphoma of the stomach in Taiwan |
- |
|
| [陳立宗] 會議論文/會議摘要 |
1999-09 |
Isolation of a Helicobacter pylori protein, FldA, associated with mucosa-associated lymphoid tissue lymphoma of the stomach |
- |
|
| [陳立宗] 期刊論文 |
2024-12-19 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer[Erratum:ESMO Open. 2024 Aug 06;9(8):Article number 103647.] |
- |
|
| [陳立宗] 期刊論文 |
2024-10 |
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study |
- |
|
| [陳立宗] 期刊論文 |
2024-08-20 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri |
- |
|
| [陳立宗] 期刊論文 |
2024-08-06 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer |
- |
|
| [陳立宗] 期刊論文 |
2024-08 |
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study |
- |
|
| [陳立宗] 期刊論文 |
2024-06-17 |
Plain language summary of the FOENIX-CCA2 study: Futibatinib for people with advanced bile duct cancer |
- |
|
| [陳立宗] 期刊論文 |
2024-05 |
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer |
- |
|
| [陳立宗] 期刊論文 |
2024-02-20 |
Chromatin remodeling-related PRDM1 increases stomach cancer proliferation and is counteracted by bromodomain inhibitor |
- |
|
| [陳立宗] 期刊論文 |
2024-02-15 |
Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance via the NTSR1/Akt pathway |
- |
|
| [陳立宗] 期刊論文 |
2024-02-13 |
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: A multicenter study in Taiwan |
- |
|
| [陳立宗] 期刊論文 |
2023-11-22 |
The prognosis performance of a neutrophil- and lymphocyte-associated gene mutation score in a head and neck cancer cohort |
- |
|
| [陳立宗] 期刊論文 |
2023-11 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer |
- |
|
| [陳立宗] 期刊論文 |
2023-10 |
The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: A noninterventional, uncontrolled multicenter study |
- |
|
| [陳立宗] 期刊論文 |
2023-09-01 |
The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. a cross sectional study |
- |
|
| [陳立宗] 期刊論文 |
2023-08-15 |
Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination |
- |
|
| [陳立宗] 期刊論文 |
2023-08 |
The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study |
- |
|
| [陳立宗] 期刊論文 |
2023-05-24 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer |
- |
|
| [陳立宗] 期刊論文 |
2023-05-01 |
The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy |
- |
|
| [陳立宗] 期刊論文 |
2023-02-24 |
Deciphering the functions of telomerase reverse transcriptase in head and neck cancer |
- |
|
| [陳立宗] 期刊論文 |
2023-02-05 |
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer |
- |
|
| [陳立宗] 期刊論文 |
2023-02 |
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan |
- |
|
| [陳立宗] 期刊論文 |
2023-01-21 |
Adjuvant therapy in biliary tract cancers: Oral fluoropyrimidine as a beginning |
- |
|
| [陳立宗] 期刊論文 |
2023-01-19 |
Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma |
- |
|
| [陳立宗] 期刊論文 |
2022-12-28 |
Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan |
- |
|
| [陳立宗] 期刊論文 |
2022-12-15 |
Skp2-mediated Zeb1 expression facilitates cancer migration by a ubiquitination-independent pathway |
- |
|
| [陳立宗] 期刊論文 |
2022-10 |
Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract Cancer: A phase II T1219 study |
- |
|
| [陳立宗] 期刊論文 |
2022-09 |
Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: Expert recommendations from Hong Kong, Singapore, and Taiwan |
- |
|
| [陳立宗] 期刊論文 |
2022-06-22 |
Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study |
- |
|
| [陳立宗] 期刊論文 |
2022-06-02 |
Trial Designs for integrating novel therapeutics into the management of intermediate-stage hepatocellular carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2022-05-15 |
Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: A single institution experience |
- |
|
| [陳立宗] 期刊論文 |
2022-04 |
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study |
- |
|
| [陳立宗] 期刊論文 |
2022-04 |
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials |
- |
|
| [陳立宗] 期刊論文 |
2022-02-24 |
Semaphorin 6C suppresses proliferation of pancreatic cancer cells via inhibition of the AKT/GSK3/beta-catenin/cyclin D1 pathway |
- |
|
| [陳立宗] 期刊論文 |
2022-02-16 |
Current status of the spectrum and therapeutics of helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma |
- |
|
| [陳立宗] 期刊論文 |
2022-02-15 |
Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1 |
- |
|
| [陳立宗] 期刊論文 |
2022-02 |
Incidence and survival variations of upper tract urothelial cancer in Taiwan (2001-2010) |
- |
|
| [陳立宗] 期刊論文 |
2022-02 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial |
- |
|
| [陳立宗] 期刊論文 |
2022-01 |
Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation |
- |
|
| [陳立宗] 期刊論文 |
2022-01 |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study |
- |
|
| [陳立宗] 期刊論文 |
2021-11-12 |
The prognostic and predictive role of chromogranin a in gastroenteropancreatic neuroendocrine tumors - A single-center experience |
- |
|
| [陳立宗] 期刊論文 |
2021-10 |
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study |
- |
|
| [陳立宗] 期刊論文 |
2021-07-23 |
AUY922 induces retinal toxicity through attenuating TRPM1 |
- |
|
| [陳立宗] 期刊論文 |
2021-07-15 |
How may ramucirumab help improve treatment outcome for patients with gastrointestinal cancers? |
- |
|
| [陳立宗] 期刊論文 |
2021-07 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab |
- |
|
| [陳立宗] 期刊論文 |
2021-06-12 |
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers |
- |
|
| [陳立宗] 期刊論文 |
2021-04-28 |
Inhibition of Beta-catenin activity abolishes LKB1 loss-driven pancreatic cystadenoma in mice |
- |
|
| [陳立宗] 期刊論文 |
2021-04 |
Phase I dose-escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors |
- |
|
| [陳立宗] 期刊論文 |
2021-03-01 |
Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors |
- |
|
| [陳立宗] 期刊論文 |
2021-03 |
A phase II clinical trial on the combination therapy of PHY906 plus capecitabine in hepatocellular carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2021-01-13 |
Development of possible next line of systemic therapies for gemcitabine-resistant biliary tract cancers: A perspective from clinical trials |
- |
|
| [陳立宗] 期刊論文 |
2021-01 |
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1 |
- |
|
| [陳立宗] 期刊論文 |
2020-12-29 |
Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan |
- |
|
| [陳立宗] 期刊論文 |
2020-11-13 |
The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: Real-world experience in a Taiwanese cohort [Erraturm: Scientific Reports. 2020 May 4;10:Article number 7420.] |
- |
|
| [陳立宗] 期刊論文 |
2020-10 |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study |
- |
|
| [陳立宗] 期刊論文 |
2020-07 |
JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions |
- |
|
| [陳立宗] 期刊論文 |
2020-05-04 |
The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: Real-world experience in a Taiwanese cohort |
- |
|
| [陳立宗] 期刊論文 |
2020-05 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data |
- |
|
| [陳立宗] 期刊論文 |
2020-05 |
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer |
- |
|
| [陳立宗] 期刊論文 |
2020-04 |
Management of early stage gastro-oesophageal cancers: Expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty |
- |
|
| [陳立宗] 期刊論文 |
2020-04 |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours |
- |
|
| [陳立宗] 期刊論文 |
2020-03 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO |
- |
|
| [陳立宗] 期刊論文 |
2020-02 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study |
- |
|
| [陳立宗] 期刊論文 |
2020-01 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer |
- |
|
| [陳立宗] 期刊論文 |
2020-01 |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma–TCOG T1211 study |
- |
|
| [陳立宗] 期刊論文 |
2020-01 |
Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: Subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial |
- |
|
| [陳立宗] 期刊論文 |
2019-10 |
The epidemiology of gastric cancers in the era of Helicobacter pylori eradication: A nation-wide cancer registry-based study in Taiwan |
- |
|
| [陳立宗] 期刊論文 |
2019-10 |
A randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FO |
- |
|
| [陳立宗] 期刊論文 |
2019-09 |
Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors |
- |
|
| [陳立宗] 期刊論文 |
2019-09 |
Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8 |
- |
|
| [陳立宗] 期刊論文 |
2019-07-28 |
Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer |
- |
|
| [陳立宗] 期刊論文 |
2019-06-21 |
Identification of phenothiazine as an ETV1targeting agent in gastrointestinal stromal tumors using the Connectivity Map |
- |
|
| [陳立宗] 期刊論文 |
2019-06 |
Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: A study protocol |
- |
|
| [陳立宗] 期刊論文 |
2019-05-20 |
Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer |
- |
|
| [陳立宗] 期刊論文 |
2019-05 |
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial |
- |
|
| [陳立宗] 期刊論文 |
2019-04-17 |
Novel insights of lymphomagenesis of helicobacter pylori-dependent gastric mucosa-associated lymphoid tissue lymphoma |
- |
|
| [陳立宗] 期刊論文 |
2019-04-08 |
Predominant global glomerulosclerosis in patients of upper urinary tract urothelial carcinoma with pre-existing renal function impairment is a predictor of poor renal outcomes |
- |
|
| [陳立宗] 期刊論文 |
2019-03 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens |
- |
|
| [陳立宗] 期刊論文 |
2019-03 |
Foreword |
- |
|
| [陳立宗] 期刊論文 |
2019-02 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (attraction-4) |
- |
|
| [陳立宗] 期刊論文 |
2019-02 |
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors |
- |
|
| [陳立宗] 期刊論文 |
2019-01 |
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin |
- |
|
| [陳立宗] 期刊論文 |
2019-01 |
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS |
- |
|
| [陳立宗] 期刊論文 |
2019-01 |
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS |
- |
|
| [陳立宗] 期刊論文 |
2018-11-13 |
From friend to enemy: Dissecting the functional alteration of immunoregulatory components during pancreatic tumorigenesis |
- |
|
| [陳立宗] 期刊論文 |
2018-11-07 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial |
- |
|
| [陳立宗] 期刊論文 |
2018-08-24 |
BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor |
- |
|
| [陳立宗] 期刊論文 |
2018-06 |
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2018-03 |
Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use |
- |
|
| [陳立宗] 期刊論文 |
2018-03 |
Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy |
- |
|
| [陳立宗] 期刊論文 |
2018-01 |
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS |
- |
|
| [陳立宗] 期刊論文 |
2018-01 |
Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma |
- |
|
| [陳立宗] 期刊論文 |
2017-12 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial |
- |
|
| [陳立宗] 期刊論文 |
2017-10-09 |
Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors |
- |
|
| [陳立宗] 期刊論文 |
2017-10 |
Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review |
- |
|
| [陳立宗] 期刊論文 |
2017-10 |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma |
- |
|
| [陳立宗] 期刊論文 |
2017-09-16 |
The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors |
- |
|
| [陳立宗] 期刊論文 |
2017-09 |
KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the KrasG12D p53flox/flox model |
- |
|
| [陳立宗] 期刊論文 |
2017-09 |
A phase II study of Arginine Deiminase (ADI-PEG20) in relapsed/refractory or poor-risk acute myeloid leukemia patients |
- |
|
| [陳立宗] 期刊論文 |
2017-08 |
Overexpressed fatty acid synthase in gastrointestinal stromal tumors: Targeting a progression-associated metabolic driver enhances the antitumor effect of imatinib |
- |
|
| [陳立宗] 期刊論文 |
2017-08 |
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo |
- |
|
| [陳立宗] 期刊論文 |
2017-07 |
A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17 |
- |
|
| [陳立宗] 期刊論文 |
2017-05 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: A Q-TWiST analysis |
- |
|
| [陳立宗] 期刊論文 |
2017-02 |
Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: Applicability to clinical situations |
- |
|
| [陳立宗] 期刊論文 |
2017-02 |
The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21) |
- |
|
| [陳立宗] 期刊論文 |
2017-02 |
Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells |
- |
|
| [陳立宗] 期刊論文 |
2017-01 |
Expressions of the CagA protein and CagA-signaling molecules predict H. pylori-dependence of early-stage gastric DLBCL |
- |
|
| [陳立宗] 期刊論文 |
2016-12 |
The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan |
- |
|
| [陳立宗] 期刊論文 |
2016-11-21 |
A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors |
- |
|
| [陳立宗] 期刊論文 |
2016-10 |
Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor |
- |
|
| [陳立宗] 期刊論文 |
2016-08 |
Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2016-07 |
Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer |
- |
|
| [陳立宗] 期刊論文 |
2016-05-14 |
Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply |
- |
|
| [陳立宗] 期刊論文 |
2016-05-03 |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer |
- |
|
| [陳立宗] 期刊論文 |
2016-02 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial |
- |
|
| [陳立宗] 期刊論文 |
2016-01 |
Investigating the association between periodontal disease and risk of pancreatic cancer |
- |
|
| [陳立宗] 期刊論文 |
2016-01 |
S-1 with leucovorin for gastric cancer: How far can it go? |
- |
|
| [陳立宗] 期刊論文 |
2015-10 |
Epigenetic regulation in the carcinogenesis of cholangiocarcinoma |
- |
|
| [陳立宗] 期刊論文 |
2015-10 |
Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells |
- |
|
| [陳立宗] 期刊論文 |
2015-09 |
AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-kappaB activation |
- |
|
| [陳立宗] 期刊論文 |
2015-08 |
Primary gastrointestinal stromal tumor of the liver in an anorectal melanoma survivor: A case report |
- |
|
| [陳立宗] 期刊論文 |
2015-07 |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review |
- |
|
| [陳立宗] 期刊論文 |
2015-05 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer |
- |
|
| [陳立宗] 期刊論文 |
2015-04-13 |
Association of dialysis with the risks of cancers |
- |
|
| [陳立宗] 期刊論文 |
2015-04 |
The potent activation of Ca2+-activated K+ current by NVP-AUY922 in the human pancreatic duct cell line (PANC-1) possibly independent of heat shock protein 90 inhibition |
- |
|
| [陳立宗] 期刊論文 |
2015-03 |
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients |
- |
|
| [陳立宗] 期刊論文 |
2015-03 |
Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1 |
- |
|
| [陳立宗] 期刊論文 |
2014-12-01 |
AMACR amplification in myxofibrosarcomas: A mechanism of overexpression that promotes cell proliferation with therapeutic relevance |
- |
|
| [陳立宗] 期刊論文 |
2014-11-30 |
MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors |
- |
|
| [陳立宗] 期刊論文 |
2014-11 |
Downregulated MTAP expression in myxofibrosarcoma: A characterization of inactivating mechanisms, tumor suppressive function, and therapeutic relevance |
- |
|
| [陳立宗] 期刊論文 |
2014-10-18 |
AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: A driver of cell proliferation indicating adverse prognosis |
- |
|
| [陳立宗] 期刊論文 |
2014-10-10 |
Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphoma |
- |
|
| [陳立宗] 期刊論文 |
2014-10 |
Stimulation of electroporation-induced inward currents in glioblastoma cell lines by the heat shock protein inhibitor AUY922 |
- |
|
| [陳立宗] 期刊論文 |
2014-09 |
High effectiveness of triptolide, an active diterpenoid triepoxide, in suppressing Kir-channel currents from human glioma cells |
- |
|
| [陳立宗] 期刊論文 |
2014-09 |
Adaptation of international guidelines for metastatic colorectal cancer: An Asian consensus |
- |
|
| [陳立宗] 期刊論文 |
2014-07-02 |
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib the EVOLVE-1 randomized clinical trial |
- |
|
| [陳立宗] 期刊論文 |
2014-07 |
Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of High-Dose 5-Fluorouracil and Leucovorin as first-line treatment for patients with advanced gastric cancer |
- |
|
| [陳立宗] 期刊論文 |
2014-06-20 |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity |
- |
|
| [陳立宗] 期刊論文 |
2014-03 |
Overexpression of CDC28 protein kinase regulatory subunit 1B confers an independent prognostic factor in nasopharyngeal carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2014-02 |
BCL6 overexpression is associated with decreased p19ARF expression and confers an independent prognosticator in gallbladder carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2013-12 |
Nicotinamide N-methyltransferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2013-12 |
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2013-12 |
Terlipressin-induced hyponatremic encephalopathy in a noncirrhotic patient |
- |
|
| [陳立宗] 期刊論文 |
2013-11 |
Management of gastric cancer in Asia: Resource-stratified guidelines |
- |
|
| [陳立宗] 期刊論文 |
2013-10 |
Clinicopathological significance of HuR expression in gallbladder carcinoma: With special emphasis on the implications of its nuclear and cytoplasmic expression |
- |
|
| [陳立宗] 期刊論文 |
2013-08 |
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer |
- |
|
| [陳立宗] 期刊論文 |
2013-07-23 |
IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder |
- |
|
| [陳立宗] 期刊論文 |
2013-07-22 |
Medical risk factors associated with cholangiocarcinoma in taiwan: A population-based case-control study |
- |
|
| [陳立宗] 期刊論文 |
2013-06-21 |
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma |
- |
|
| [陳立宗] 期刊論文 |
2013-06-20 |
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations |
- |
|
| [陳立宗] 期刊論文 |
2013-06 |
No evidence of IGH-MALT1-translocation in the Ma-1 cell line-A reply |
- |
|
| [陳立宗] 期刊論文 |
2013-06 |
ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: Aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance |
- |
|
| [陳立宗] 期刊論文 |
2013-05 |
Loss of epithelial membrane protein-2 expression confers an independent prognosticator in gallbladder carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2013-05 |
E2F transcription factor 1 overexpression as a poor prognostic factor in patients with nasopharyngeal carcinomas |
- |
|
| [陳立宗] 期刊論文 |
2013-04 |
Fatty acid synthase overexpression confers an independent prognosticator and associates with radiation resistance in nasopharyngeal carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2013-04 |
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential |
- |
|
| [陳立宗] 期刊論文 |
2013-02 |
Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors |
- |
|
| [陳立宗] 期刊論文 |
2013-01 |
Randomised clinical trial: Comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2012-12-21 |
HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2012-11 |
Potential role of KLF10 in the regulation of gemcitabine resistance in pancreatic cancer cells |
- |
|
| [陳立宗] 期刊論文 |
2012-09 |
Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2012-09 |
Digestive cancer management in Asia: Position statements: A report on GI oncology summit in 2011 |
- |
|
| [陳立宗] 期刊論文 |
2012-08 |
Rsf-1 expression in rectal cancer: With special emphasis on the independent prognostic value after neoadjuvant chemoradiation |
- |
|
| [陳立宗] 期刊論文 |
2012-08 |
Contribution of blocked potassium current conductance and increased conductance of persistent sodium current to the afterdischarge in myelinated neuron |
- |
|
| [陳立宗] 期刊論文 |
2012-07 |
Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis |
- |
|
| [陳立宗] 期刊論文 |
2012-05-24 |
Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas |
- |
|
| [陳立宗] 期刊論文 |
2012-04 |
Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator |
- |
|
| [陳立宗] 期刊論文 |
2012-02 |
EGFR nuclear import in gallbladder carcinoma: Nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact |
- |
|
| [陳立宗] 期刊論文 |
2012-01 |
Long-term results of a randomized, observation-controlled, phase III trial of adjuvant Interferon alfa-2b in hepatocellular carcinoma after curative resection |
- |
|
| [陳立宗] 期刊論文 |
2011-12 |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-Fluorouracil/Leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study |
- |
|
| [陳立宗] 期刊論文 |
2011-12 |
t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement |
- |
|
| [陳立宗] 期刊論文 |
2011-11 |
Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter Pylori-independent gastric MALT lymphoma |
- |
|
| [陳立宗] 期刊論文 |
2011-09 |
Nanovector-based therapies in advanced pancreatic cancer |
- |
|
| [陳立宗] 期刊論文 |
2011-08-17 |
A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan |
- |
|
| [陳立宗] 期刊論文 |
2011-08 |
Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer |
- |
|
| [陳立宗] 期刊論文 |
2011-07 |
Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan |
- |
|
| [陳立宗] 期刊論文 |
2011-05 |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001 |
- |
|
| [陳立宗] 期刊論文 |
2011-03-07 |
2-Amino-3,4,5-Trimethoxybenzophenones as Potent Tubulin Polymerization Inhibitors |
- |
|
| [陳立宗] 期刊論文 |
2010-10 |
A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer |
- |
|
| [陳立宗] 期刊論文 |
2010-04 |
Unusual presentation of multiple pathologic bone fractures in a patient with gastric mucosa-associated lymphoid tissue lymphoma |
- |
|
| [陳立宗] 期刊論文 |
2010 |
Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach |
- |
|
| [陳立宗] 期刊論文 |
2009-11 |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer |
- |
|
| [陳立宗] 期刊論文 |
2009-11 |
Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009 |
- |
|
| [陳立宗] 期刊論文 |
2009-07 |
The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated NG108-15 neuronal cells |
- |
|
| [陳立宗] 期刊論文 |
2008-12 |
Medical resource utilizations and economic burden in Chinese cancer patients with chemotherapy-induced anemia: A populational database study |
- |
|
| [陳立宗] 期刊論文 |
2008-10 |
Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma |
- |
|
| [陳立宗] 期刊論文 |
2008-09 |
Unusual presentation of metastatic hepatocellular carcinoma in the nasal septum: A case report and review of the literature |
- |
|
| [陳立宗] 期刊論文 |
2008-06 |
Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors |
- |
|
| [陳立宗] 期刊論文 |
2008-02 |
Long-term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma - Need for a revisit of surgical treatment |
- |
|
| [陳立宗] 期刊論文 |
2008 |
Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis |
- |
|
| [陳立宗] 期刊論文 |
2008 |
PDGFRA one nucleotide deletion: A novel mutation of systemic mastocytosis associated with chronic myelomonocytic leukemia |
- |
|
| [陳立宗] 期刊論文 |
2007-02 |
Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach - significance of tumour cell clonality and BCL10 expression |
- |
|
| [陳立宗] 期刊論文 |
2006-12 |
Low dose of thalidomide can be effective in advanced hepatocellular carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2006-07-20 |
Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma |
- |
|
| [陳立宗] 期刊論文 |
2006-07-17 |
An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer |
- |
|
| [陳立宗] 期刊論文 |
2006-05 |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer |
- |
|
| [陳立宗] 期刊論文 |
2006-03 |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer |
- |
|
| [陳立宗] 期刊論文 |
2005-11 |
Clinical and endoscopic features of non-steroidal anti-inflammatory drug-induced colorectal ulcerations |
- |
|
| [陳立宗] 期刊論文 |
2005-08-01 |
Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21) |
- |
|
| [陳立宗] 期刊論文 |
2005-06 |
Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis |
- |
|
| [陳立宗] 期刊論文 |
2005-05 |
Effect of thalidomide in hepatocellular carcinoma: Assessment with power Doppler US and analysis of circulating angiogenic factors |
- |
|
| [陳立宗] 期刊論文 |
2004-09-01 |
Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas |
- |
|
| [陳立宗] 期刊論文 |
2004-08 |
Effect of interieukin-1 beta and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma |
- |
|
| [陳立宗] 期刊論文 |
2004-07-10 |
Promoter polymorphisms of tumor necrosis factor-alpha are associated with risk of gastric mucosa-associated lymphoid tissue lymphoma |
- |
|
| [陳立宗] 期刊論文 |
2004-06 |
Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin |
- |
|
| [陳立宗] 期刊論文 |
2004-01-01 |
Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells |
- |
|
| [陳立宗] 期刊論文 |
2004 |
Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens |
- |
|
| [陳立宗] 期刊論文 |
2004 |
Hepatocellular carcinoma with intra-atrial tumor thrombi - A report of three cases responsive to thalidomide treatment and literature review |
- |
|
| [陳立宗] 期刊論文 |
2003-11-17 |
New analogues of AHMA as potential antitumor agents: Synthesis and biological activity |
- |
|
| [陳立宗] 期刊論文 |
2003-06-15 |
Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent |
- |
|
| [陳立宗] 期刊論文 |
2003 |
Low-dose thalidomide treatment for advanced hepatocellular carcinoma |
- |
|
| [陳立宗] 期刊論文 |
2002-09-26 |
Antitumor AHMA linked to DNA minor groove binding agents: Synthesis and biological evaluation |
- |
|
| [陳立宗] 期刊論文 |
2002-07-01 |
Novel mutation of topoisomerase I in rendering cells resistant to camptothecin |
- |
|
| [陳立宗] 期刊論文 |
2002-07 |
Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin |
- |
|
| [陳立宗] 期刊論文 |
2001-11-15 |
Prospective study of Helicobacter pylori eradication therapy in stage I-E high-grade mucosa-associated lymphoid tissue lymphoma of the stomach |
- |
|
| [陳立宗] 期刊論文 |
2001-03 |
Evaluation of GL331 in combination with paclitaxel: GL331's interference with paclitaxel-induced cell cycle perturbation and apoptosis |
- |
|
| [陳立宗] 期刊論文 |
2001-01-01 |
Comparison of MALT and non-MALT primary large cell lymphoma of the stomach - Does histologic evidence of MALT affect chemotherapy response? |
- |
|
| [陳立宗] 期刊論文 |
2000-07 |
Chemotherapy alone versus surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach |
- |
|
| [陳立宗] 期刊論文 |
1999-07 |
Isolation of a Helicobacter pylori protein, FldA, associated with mucose-associated lymphoid tissue lymphoma of the stomach |
- |
|
| [陳立宗] 期刊論文 |
1999-01 |
Lung cancer mimicking acute myocardial infarction on electrocardiogram |
- |
|
| [陳立宗] 期刊論文 |
1998-07 |
Percutaneous transhepatic duodenal drainage as an alternative approach in afferent loop obstruction with secondary obstructive jaundice in recurrent gastric cancer |
- |
|
| [顏伶汝] 期刊論文 |
2021-09-10 |
Stromal galectin-1 promotes colorectal cancer cancer-initiating cell features and disease dissemination through SOX9 and Beta-catenin: Development of niche-based biomarkers |
- |
|
| [黃智興] 期刊論文 |
2018-02-01 |
Myeloid-derived macrophages and secreted HSP90alpha induce pancreatic ductal adenocarcinoma development |
- |
|
| [黃秀芬] 會議論文/會議摘要 |
2020-05 |
Establishing the common oncology data model for the national biobank consortium of Taiwan |
- |
|
